RLMD (Relmada Therapeutics) Research & Development: $23.02 Mil (TTM As of Mar. 2026)


RLMD Relmada Therapeutics Inc RLMD
29 GF Score
Price $6.67
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics Research & Development?

Relmada Therapeutics RLMD +3.72% 29 Research & Development is $23.02 Mil as of Mar. 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Relmada Therapeutics's Research & Development for the three months ended in Mar. 2026 was $8.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $23.02 Mil.

Relmada Therapeutics  (NAS:RLMD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Relmada Therapeutics Research & Development Related Terms

Relmada Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Relmada Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics Research & Development Chart

Relmada Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.62 113.32 54.81 46.18 26.88

Relmada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.95 2.82 4.04 8.07 8.09
RLMD
29GF Score
Relmada Therapeutics Inc RLMD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $23.02 Mil mean?
Relmada Therapeutics (RLMD) has a Research & Development of $23.02 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Relmada Therapeutics and its competitors.
Is Relmada Therapeutics' Research & Development too high?
Relmada Therapeutics' current Research & Development is $23.02 Mil. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' Research & Development compare to ALLO and PHAT?
Relmada Therapeutics' Research & Development of $23.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Relmada Therapeutics and its competitors. Relmada Therapeutics's current Research & Development is $23.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current Research & Development of $23.02 Mil. The current Research & Development is $23.02 Mil. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current Research & Development is $23.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Other Exchanges 4E2:Germany
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score

Get the complete analysis for RLMD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.67
Price